Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer

Por Katayama, Ryohei, Kobayashi, Yuka, Friboulet, Luc, Lockerman, Elizabeth. L., Koike, Sumie, Shaw, Alice T., Engelman, Jeffrey A., Fujita, Naoya
Publicado no Clin Cancer Res (2014)

The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies

Por Niederst, Matthew J., Hu, Haichuan, Mulvey, Hillary E., Lockerman, Elizabeth L., Garcia, Angel R., Piotrowska, Zofia, Sequist, Lecia V., Engelman, Jeffrey A.
Publicado no Clin Cancer Res (2015)

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

Por Rothenberg, S Michael, Concannon, Kyle, Cullen, Sarah, Boulay, Gaylor, Turke, Alexa B, Faber, Anthony C, Lockerman, Elizabeth L, Rivera, Miguel N, Engelman, Jeffrey A, Maheswaran, Shyamala, Haber, Daniel A
Publicado no eLife (2015)

Two novel ALK mutations mediate acquired resistance to the next generation ALK inhibitor alectinib

Por Katayama, Ryohei, Friboulet, Luc, Koike, Sumie, Lockerman, Elizabeth L., Khan, Tahsin M., Gainor, Justin F., Iafrate, A. John, Takeuchi, Kengo, Taiji, Makoto, Okuno, Yasushi, Fujita, Naoya, Engelman, Jeffrey A., Shaw, Alice T.
Publicado no Clin Cancer Res (2014)

CDK 4/6 inhibitors sensitize PIK3CA Mutant Breast Cancer to PI3K inhibitors

Por Vora, Sadhna R., Juric, Dejan, Kim, Nayoon, Mino-Kenudson, Mari, Huynh, Tiffany, Costa, Carlotta, Lockerman, Elizabeth L., Pollack, Sarah F., Liu, Manway, Li, Xiaoyan, Lehar, Joseph, Wiesmann, Marion, Wartmann, Markus, Chen, Yan, Cao, Z. Alexander, Pinzon-Ortiz, Maria, Kim, Sunkyu, Schlegel, Robert, Huang, Alan, Engelman, Jeffrey A.
Publicado em 2014

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

Por Awad, Mark M., Katayama, Ryohei, McTigue, Michele, Liu, Wei, Deng, Ya-Li, Brooun, Alexei, Friboulet, Luc, Huang, Donghui, Falk, Matthew D., Timofeevski, Sergei, Wilner, Keith D., Lockerman, Elizabeth L., Khan, Tahsin M., Mahmood, Sidra, Gainor, Justin F., Digumarthy, Subba R., Stone, James R., Mino-Kenudson, Mari, Christensen, James G., Iafrate, A. John, Engelman, Jeffrey A., Shaw, Alice T.
Publicado em 2013

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

Por Friboulet, Luc, Li, Nanxin, Katayama, Ryohei, Lee, Christian C., Gainor, Justin F., Crystal, Adam S., Michellys, Pierre-Yves, Awad, Mark M., Yanagitani, Noriko, Kim, Sungjoon, Pferdekamper, AnneMarie C., Li, Jie, Kasibhatla, Shailaja, Sun, Frank, Sun, Xiuying, Hua, Su, McNamara, Peter, Mahmood, Sidra, Lockerman, Elizabeth L., Fujita, Naoya, Nishio, Makoto, Harris, Jennifer L., Shaw, Alice T., Engelman, Jeffrey A.
Publicado em 2014

Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third Generation EGFR Inhibitor

Por Piotrowska, Zofia, Niederst, Matthew J., Karlovich, Chris A., Wakelee, Heather A., Neal, Joel W., Mino-Kenudson, Mari, Fulton, Linnea, Hata, Aaron N., Lockerman, Elizabeth L., Kalsy, Anuj, Digumarthy, Subba, Muzikansky, Alona, Raponi, Mitch, Garcia, Angel R., Mulvey, Hillary E., Parks, Melissa K., DiCecca, Richard H., Dias-Santagata, Dora, Iafrate, A. John, Shaw, Alice T., Allen, Andrew R., Engelman, Jeffrey A., Sequist, Lecia V.
Publicado no Cancer Discov (2015)

Patient-derived Models of Acquired Resistance Can Identify Effective Drug Combinations for Cancer

Por Crystal, Adam S., Shaw, Alice T., Sequist, Lecia V., Friboulet, Luc, Niederst, Matthew J., Lockerman, Elizabeth L., Frias, Rosa L., Gainor, Justin F., Amzallag, Arnaud, Greninger, Patricia, Lee, Dana, Kalsy, Anuj, Gomez-Caraballo, Maria, Elamine, Leila, Howe, Emily, Hur, Wooyoung, Lifshits, Eugene, Robinson, Hayley E., Katayama, Ryohei, Faber, Anthony C., Awad, Mark M., Ramaswamy, Sridhar, Mino-Kenudson, Mari, Iafrate, A. John, Benes, Cyril H., Engelman, Jeffrey A.
Publicado no Science (2014)

Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations

Por Ahronian, Leanne G., Sennott, Erin M., Van Allen, Eliezer M., Wagle, Nikhil, Kwak, Eunice L., Faris, Jason E., Godfrey, Jason T., Nishimura, Koki, Lynch, Kerry D., Mermel, Craig H., Lockerman, Elizabeth L., Kalsy, Anuj, Gurski, Joseph M., Bahl, Samira, Anderka, Kristin, Green, Lisa M., Lennon, Niall J., Huynh, Tiffany G., Mino-Kenudson, Mari, Getz, Gad, Dias-Santagata, Dora, Iafrate, A. John, Engelman, Jeffrey A., Garraway, Levi A., Corcoran, Ryan B.
Publicado no Cancer Discov (2015)

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Por Niederst, Matthew J., Sequist, Lecia V., Poirier, John T., Mermel, Craig H., Lockerman, Elizabeth L., Garcia, Angel R., Katayama, Ryohei, Costa, Carlotta, Ross, Kenneth N., Moran, Teresa, Howe, Emily, Fulton, Linnea E., Mulvey, Hillary E., Bernardo, Lindsay A., Mohamoud, Farhiya, Miyoshi, Norikatsu, VanderLaan, Paul A., Costa, Daniel B., Jänne, Pasi A., Borger, Darrell R., Ramaswamy, Sridhar, Shioda, Toshi, Iafrate, Anthony J., Getz, Gad, Rudin, Charles M., Mino-Kenudson, Mari, Engelman, Jeffrey A.
Publicado no Nat Commun (2015)